{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"65","upperLimit":"96","value":"79"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"description":"PFS rate at 12 months is defined as the percentage of participants who are alive and progression-free at 12 months. Progression is exclusively defined as a patient with progressive disease while receiving treatment with lenalidomide in combination with dexamethasone. Progression was defined as any one or more of the following: An increase of 25% from lowest confirmed response in:\n\n* Serum M-component (absolute increase \\>= 0.5g/dl)\n* Urine M-component (absolute increase \\>= 200mg/24hour\n* Difference between involved and uninvolved Free Light Chain levels (absolute increase \\>= 10mg/dl\n* Bone marrow plasma cell percentage (absolute increase of \\>=10%)","dispersionType":"95% Confidence Interval","groups":[{"description":"Lenalidomide: 25mg once daily orally with food on days 1-21 of 28 day cycle until progression or to a maximum of 18 cycles.\n\nDexamethasone: 10-40 mg once weekly (days 1, 8, 15, \\& 22) orally with food until progression.","id":"OG000","title":"Lenalidomide With On-Demand Dexamethasone"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"12 months from registration","title":"Progression-free Survival (PFS) Rate at 12 Months","type":"PRIMARY","unitOfMeasure":"percentage of participants"}